-
Exit Strategies in Patients With Stable MS: Cost-Effectiveness of Extended Interval Dosing of Ocrelizumab and Natalizumab vs. De-escalating to Cladribine
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Aztreonam Avibactam (ATMAVI) ± Metronidazole (MTZ) for the Treatment of Complicated Intra-Abdominal Infections (cIAIs) and Ventilator-Associated Hospital-Acquired Pneumonia (HAP/VAP) Caused by Suspected MBL-Producing...
Sep 9, 2025, 16:22 PM -
Developing Best Practice for Generative AI in Health Economic Evaluation: Evidence From a Systematic Review and Stakeholder Engagement
Sep 9, 2025, 16:22 PM -
US Payer Assessment of the Utility and Impact of Value Dossiers on Decision Making
Sep 9, 2025, 16:22 PM -
Fitting Flexible Survival Models to Landmark Survival Estimates in R
Sep 9, 2025, 16:22 PM -
Comparison of the Early Access and Postmarket Evaluation Systems in South Korea and Germany’s DIGA
Sep 9, 2025, 16:22 PM -
The Longevity Conundrum: Population Aging in the UK
Sep 9, 2025, 16:22 PM -
Associations of Product-Specific and Clinical Evidence Quality Characteristics With Health Technology Assessment Outcomes: A Quantitative Assessment of Appraisals for Drugs for Rare Diseases in England and Germany
Sep 9, 2025, 16:22 PM -
The Perils of Treatment Crossover in Clinical Trials
Sep 9, 2025, 16:22 PM -
Building Risk-Sharing Agreements in Chile: Feasibility and Policy Options
Sep 9, 2025, 16:22 PM -
Impact of Real-World Effectiveness vs. Previous Assumptions on Estimates of Economic and Clinical Benefit of 20-Valent Pneumococcal Conjugate Vaccine in Adults Across Countries
Sep 9, 2025, 16:22 PM -
Pricing Analysis of Value-Added Medicines (VAMs) in Europe: A Call for Recognition of Patient-Centric Innovation
Sep 9, 2025, 16:22 PM -
Medical Resource Utilizations and Economic Burden of Chemotherapy-Induced Anemia in Chinese Population: A Multicenter Retrospective Study
Sep 9, 2025, 16:22 PM -
Identification of Real-World Data to Study HAE Unmet Need: A Targeted Literature Review
Sep 9, 2025, 16:22 PM -
The Role of Unpaid Work in Measuring the Social Costs of Disease
Sep 9, 2025, 16:22 PM -
Economic Evaluation of Surfactant Therapy for Neonatal Respiratory Distress Syndrome: 5-Year Real-World Evidence on Poractant Alfa vs. Beractant From the IMSS Perspective in Mexico
Sep 9, 2025, 16:22 PM -
The Uptake of R in NICE HTA: Insights From Technology Assessment Groups
Sep 9, 2025, 16:22 PM -
The Cost-Effectiveness of Targeted-Release Form (TRF)-Budesonide for the Treatment of Adult Population With Immunoglobulin A Nephropathy (IgAN) in Greece
Sep 9, 2025, 16:22 PM -
Impact of RFID-Enabled Unit-Level Traceability on Resource Utilization and Quality Assurance in Prefilled Syringe Production
Sep 9, 2025, 16:22 PM -
Understanding Trends and Opinions on More Environmentally Friendly Healthcare: A Clinician Survey
Sep 9, 2025, 16:22 PM
